Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A clinician-reviewed guide to suvorexant pharmacogenomics, ethnicity-stratified trial data, and practical dose-adjustment guidance for Hispanic / Latino patients prescribed Belsomra.
Read clinical reviewEvidence review of suvorexant (Belsomra) efficacy in South Asian populations, covering CYP3A4 pharmacogenomics, BMI-adjusted dosing, and ethnicity-stratified trial data.
Read clinical reviewEvidence-based review of suvorexant (Belsomra) pharmacogenomics, dosing considerations, and safety data relevant to Black and African ancestry populations.
Read clinical reviewEvidence-based review of suvorexant pharmacogenomics, CYP3A4 metabolism, and dosing considerations specific to Hispanic and Latino populations, including diabetes comorbidity data and ethnicity-stratified trial results.
Read clinical reviewEvidence-based review of how suvorexant (Belsomra) safety, metabolism, and dosing may differ in South Asian populations due to pharmacogenomic variation, body composition, and CYP3A4 polymorphisms.
Read clinical reviewA clinical review of suvorexant (Belsomra) efficacy differences in East Asian patients, covering CYP3A4/CYP2C19 pharmacogenomics, ethnicity-stratified trial data, FDA-approved dosing adjustments, and prescribing guidance.
Read clinical reviewA clinical review of suvorexant (Belsomra) efficacy and pharmacogenomic differences in Hispanic and Latino patients, including CYP3A4 variation, orexin receptor biology, and dosing considerations relevant to this population.
Read clinical review